CHM-1
CAS No. 154554-41-3
CHM-1 ( NSC656158 )
产品货号. M27612 CAS No. 154554-41-3
CHM-1 is an inducer of apoptosis, and displays potent antitumor ability in human hepatocellular carcinoma by activation of Cdc2 kinase activity. CHM-1 inhibits tubulin polymerization in vitro and in vivo.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
2MG | ¥656 | 有现货 |
|
5MG | ¥1077 | 有现货 |
|
10MG | ¥1798 | 有现货 |
|
25MG | ¥3872 | 有现货 |
|
50MG | ¥5557 | 有现货 |
|
100MG | ¥8076 | 有现货 |
|
500MG | ¥16119 | 有现货 |
|
1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称CHM-1
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述CHM-1 is an inducer of apoptosis, and displays potent antitumor ability in human hepatocellular carcinoma by activation of Cdc2 kinase activity. CHM-1 inhibits tubulin polymerization in vitro and in vivo.
-
产品描述CHM-1 is an inducer of apoptosis, and displays potent antitumor ability in human hepatocellular carcinoma by activation of Cdc2 kinase activity. CHM-1 inhibits tubulin polymerization in vitro and in vivo.(In Vitro):CHM-1 (0-10 μM; 24 hours) significantly increased the binding of cyclin B1 to Cdc2 and induced change in expressed and phosphorylated status of G2-M regulators in HA22T cells. CHM-1 (0-100μM; 24 hours) induced significant concentration-dependent growth inhibition in HA22T, Hep3B, and HepG2 cells, with the most potent effects observed in HA22T cells with an IC50 of 0.75 μM).(In Vivo):In male severe combined immunodeficient mice, CHM-1 (10 mg/kg; i.p.) induced inhibition of HA22T tumor growth in a dose-dependent manner.
-
同义词NSC656158
-
通路Apoptosis
-
靶点Apoptosis
-
受体Antibiotic;P-glycoprotein
-
研究领域——
-
适应症——
化学信息
-
CAS Number154554-41-3
-
分子量283.3
-
分子式C16H10FNO3
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESFc1ccccc1-c1cc(=O)c2cc3OCOc3cc2[nH]1
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Phung-Ba V et al. Interaction of pristinamycin IA with P-glycoprotein in human intestinal epithelial cells. Eur J Pharmacol. 1995 Jan 16;288(2):187-92.
产品手册
关联产品
-
VPC-70063
VPC-70063 is an inhibitor of c-Myc-MAX. VPC-70063 exhibits Myc-Max transcriptional activity inhibition of 106% with an IC50 of 8.9 μM and Myc-Max/UBE2C downstream pathway inhibition of 94%. VPC-70063 can be used for studies about anticancer.
-
DT2216
DT2216 inhibits various Bcl-XL-dependent leukemias and cancer cells, but is significantly less toxic to platelets.DT2216 is a selective B-cell lymphoma, extremely large (BCL-XL), proteolytic targeting chimera (PROTAC).
-
Flavokawain C
Flavokawain C (FKC) a naturally occurring chalcone which can be isolated from Kava.FKC has the potential to be developed into chemotherapeutic drug for the treatment of colon adenocarcinoma.